[Treatment of osteoporosis with parathyroid hormone: evidence and perspective]
Author(s): Kaji H, Sugimoto T
Affiliation(s): Division of Endocrinology/metabolism, Neurology and Hematology/Oncology, Department of Clinical Molecular Medicine, Kobe University Graduate School of Medicine, Japan.
Publication date & source: 2005-04, Clin Calcium., 15(4):611-5.
Publication type: Review
Parathyroid hormone (PTH) is a promising bone formation-stimulating agent, and the recent large-scale randomized controlled trial (RCT) revealed that parathyroid hormone increases and reduces lumbar bone mineral density and fracture risk, respectively, more potently than bisphosphonates. Moreover, PTH is also effective for male or glucocorticoid-induced osteoporosis. However, the recent studies showed that the co administration of PTH and bisphosphonate is not good. The further accumulation of evidence about the combined or subsequent therapy is expected.
|